Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00763061 · ClinicalTrials.gov registry record · Phase 4
Travatan Versus Timoptic in Treating Open-angle Glaucoma or Ocular Hypertension
A Phase 4 study, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 4
- Development phase
- 111
- Enrollment target
NCT00763061: Completed Phase 4 study, sponsored by Alcon Research.
NCT00763061 is a Phase 4 study that has completed, run by Alcon Research. The registered enrollment target is 111 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (79% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00763061, a Phase 4 study, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 111 participants
- Enrollment target
Study Summary
To evaluate the Intraocular Pressure (IOP) lowering efficacy and safety of Travoprost 0.004% compared to Timolol 0.5% in patients with open-angle glaucoma (OAG) or ocular hypertension (OH). The study structure is a parallel design. The patients will receive treatment for 12 weeks.
Primary Outcome
Bilateral IOP measurements by Goldmann applanation were performed at 9AM and 4 PM. Two IOP measurements were taken and averaged. If the difference between the first and second reading was greater than 4 mmHg, a third reading was taken and the two nearest readings averaged.
Interventions
- DRUG Travoprost 0.004% Ophthalmic Solution (Travatan)
- DRUG Timolol 0.5% Ophthalmic Solution (Timoptic)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2006-05 |
| Est. Completion | 2008-04 |
| Phase | Phase 4 |
What the finished NCT00763061 record still lists
NCT00763061 is an interventional study that assigns participants to a tested intervention. The registered 111 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (79% lower).
The record links to 0 conditions, and to 2 interventions - of which Travoprost 0.004% Ophthalmic Solution (Travatan) is the first listed.
NCT00763061 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00763061 about?
NCT00763061 is a clinical study titled "Travatan Versus Timoptic in Treating Open-angle Glaucoma or Ocular Hypertension". To evaluate the Intraocular Pressure (IOP) lowering efficacy and safety of Travoprost 0.004% compared to Timolol 0.5% in patients with open-angle glaucoma (OAG) or ocular hypertension (OH). The study structure is a parallel design. The patients will receive treatment for 12 weeks.
What is the current status of trial NCT00763061?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 111 participants. The study started on 2006-05. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00763061?
The interventions under investigation include: Travoprost 0.004% Ophthalmic Solution (Travatan) (DRUG), Timolol 0.5% Ophthalmic Solution (Timoptic) (DRUG).
Who is sponsoring clinical trial NCT00763061?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00763061's enrollment target sits among peer trials
111 726th of 2000 higher than 1,274 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03875716 · 111 participants · NA
Study of De_Intensified Postoperative Radiation Therapy for HPV Associated Oropharyngeal Squamous Cell Carcinoma
- NCT04693468 · 111 participants · Phase 1
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
- NCT05263050 · 111 participants · Phase 2
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
- NCT05600842 · 111 participants
De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia